S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NYSEAMERICAN:PTN

Palatin Technologies - PTN Stock Forecast, Price & News

$4.02
-0.05 (-1.23%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.93
$4.60
50-Day Range
N/A
52-Week Range
$2.14
$13.00
Volume
90,688 shs
Average Volume
105,603 shs
Market Capitalization
$37.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Palatin Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,392.5% Upside
$60.00 Price Target
Short Interest
Bearish
3.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$594 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.62) to ($3.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

PTN stock logo

About Palatin Technologies (NYSEAMERICAN:PTN) Stock

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

PTN Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Palatin Receives $4.7 Million of Non-Dilutive Funding
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Palatin Announces $10 Million Registered Direct Offering
Palatin Technologies Inc. Q4 Loss decreases, but misses estimates
See More Headlines
Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

PTN Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PTN
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$60.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+1,143.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,200,000.00
Net Margins
-1,713.72%
Pretax Margin
-1,713.63%

Debt

Sales & Book Value

Annual Sales
$1.47 million
Book Value
$1.76 per share

Miscellaneous

Free Float
8,410,000
Market Cap
$37.51 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Carl Spana
    President, Chief Executive Officer & Director
  • Stephen T. Wills
    COO, CFO, Secretary, Treasurer & Executive VP
  • Michael B. Raizman
    Chief Medical Officer
  • John Dodd
    Senior Vice President-Preclinical Development
  • James E. Hattersley
    Senior Vice President-Business Development













PTN Stock - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings
or view top-rated stocks.

What is Palatin Technologies' stock price forecast for 2023?

2 analysts have issued 12 month price targets for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they expect the company's share price to reach $60.00 in the next year. This suggests a possible upside of 1,392.5% from the stock's current price.
View analysts price targets for PTN
or view top-rated stocks among Wall Street analysts.

How have PTN shares performed in 2023?

Palatin Technologies' stock was trading at $3.87 at the beginning of the year. Since then, PTN stock has increased by 3.9% and is now trading at $4.02.
View the best growth stocks for 2023 here
.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 257,200 shares, an increase of 32.0% from the December 15th total of 194,800 shares. Based on an average trading volume of 54,700 shares, the short-interest ratio is presently 4.7 days. Currently, 2.5% of the company's shares are short sold.
View Palatin Technologies' Short Interest
.

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our PTN earnings forecast
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($1.34) by $0.48. The biopharmaceutical company earned $0.87 million during the quarter, compared to the consensus estimate of $0.80 million. Palatin Technologies had a negative net margin of 1,713.72% and a negative trailing twelve-month return on equity of 169.74%.

When did Palatin Technologies' stock split?

Palatin Technologies's stock reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr.
View institutional ownership trends
.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $4.02.

How much money does Palatin Technologies make?

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $37.51 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($3.95) on an earnings per share basis.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202.

This page (NYSEAMERICAN:PTN) was last updated on 2/3/2023 by MarketBeat.com Staff